Skip to content

Glaukos GKOS Other intangible assets—net

Other intangible assets—net at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$49.06B+33.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+10.3%
Boston Scientific logo
Boston ScientificBSX
$7.06B+7.5%
AbbVie logo
AbbVieABBV
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's other intangible assets—net?
Glaukos (GKOS) reported other intangible assets—net of $133.03M in Q1 2026.
How has Glaukos's other intangible assets—net changed year-over-year?
Glaukos's other intangible assets—net decreased by 48.4% year-over-year, from $257.87M to $133.03M.
What is the long-term trend for Glaukos's other intangible assets—net?
Over 5 years (2020 to 2025), Glaukos's other intangible assets—net has grown at a -16.9% compound annual growth rate (CAGR), from $357.69M to $141.92M.